168 related articles for article (PubMed ID: 21519338)
21. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.
Bishop JR; Ellingrod VL; Moline J; Miller D
Med Sci Monit; 2006 Feb; 12(2):BR47-50. PubMed ID: 16449941
[TBL] [Abstract][Full Text] [Related]
22. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.
Haslemo T; Loryan I; Ueda N; Mannheimer B; Bertilsson L; Ingelman-Sundberg M; Molden E; Eliasson E
Clin Pharmacol Ther; 2012 Aug; 92(2):221-7. PubMed ID: 22713701
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
Erickson-Ridout KK; Zhu J; Lazarus P
Pharmacogenet Genomics; 2011 Sep; 21(9):539-51. PubMed ID: 21750471
[TBL] [Abstract][Full Text] [Related]
24. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
25. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.
Brandl EJ; Tiwari AK; Chowdhury NI; Zai CC; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
Pharmacogenomics; 2014 Mar; 15(4):423-31. PubMed ID: 24624910
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.
Gagliano SA; Tiwari AK; Freeman N; Lieberman JA; Meltzer HY; Kennedy JL; Knight J; Müller DJ
Hum Psychopharmacol; 2014 Jul; 29(4):330-5. PubMed ID: 24737441
[TBL] [Abstract][Full Text] [Related]
27. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
28. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
[TBL] [Abstract][Full Text] [Related]
30. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
31. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.
Kang SG; Lee HJ; Park YM; Choi JE; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):160-3. PubMed ID: 17804136
[TBL] [Abstract][Full Text] [Related]
32. Weight gain during treatment of bipolar I patients with olanzapine.
Hennen J; Perlis RH; Sachs G; Tohen M; Baldessarini RJ
J Clin Psychiatry; 2004 Dec; 65(12):1679-87. PubMed ID: 15641874
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.
Park YM; Choi JE; Kang SG; Koo SH; Kim L; Geum D; Lee HJ
Hum Psychopharmacol; 2011; 26(4-5):332-7. PubMed ID: 21695734
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
35. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.
Maciukiewicz M; Tiwari AK; Zai CC; Gorbovskaya I; Laughlin CP; Nurmi EL; Liebermann JA; Meltzer HY; Kennedy JL; Müller DJ
Schizophr Res; 2019 Oct; 212():204-212. PubMed ID: 31447353
[TBL] [Abstract][Full Text] [Related]
37. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?
Schwenger E; Dumontet J; Ensom MH
Clin Pharmacokinet; 2011 Jul; 50(7):415-28. PubMed ID: 21651311
[TBL] [Abstract][Full Text] [Related]
38. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
40. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Opolka JL; Rascati KL; Brown CM; Barner JC; Johnsrud MT; Gibson PJ
J Clin Psychiatry; 2003 Jun; 64(6):635-9. PubMed ID: 12823076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
